Drug and Medication Analysis & Statistics in the United Kingdom, December 2013 (p3)

61-90 of about 100 reports

Purchase Reports From Reputable Market Research Publishers

2014 Opportunities in the UK Endocrine Function Testing Market

2014 Opportunities in the UK Endocrine Function Testing Market

  • $ 1 500
  • Industry report
  • December 2013
  • by Venture Planning Group

This new 269-page report from Venture Planning Group provides a comprehensive analysis in the UK endocrine function market, including emerging tests, technologies, instrumentation, sales forecasts by ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
2014 Opportunities in the European Drugs of Abuse Testing Market

2014 Opportunities in the European Drugs of Abuse Testing Market

  • $ 4 200
  • Industry report
  • December 2013
  • by Venture Planning Group

This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, ...

  • Industries : Drug and Medication
  • Countries : Germany, United Kingdom, Italy, Spain
Diabetes – KOL Insight and Consensus Outlook Modules

Diabetes – KOL Insight and Consensus Outlook Modules

  • $ 7 495
  • Industry report
  • December 2013
  • by Firstword Pharma

Introduction The medium term: battle lines are drawn The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels of obesity and disease prevalence in both ...

  • Industries : Drug and Medication, Pathology
  • Countries : United States, United Kingdom
PharmaPoint: Atopic Dermatitis - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Atopic Dermatitis - UK Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • November 2013
  • by Global Data

PharmaPoint: Atopic Dermatitis - UK Drug Forecast and Market Analysis to 2022 Summary Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly ...

  • Industries : Pathology, Drug and Medication
  • Countries : United Kingdom
PharmaPoint: Obesity - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Obesity - UK Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • October 2013
  • by Global Data

PharmaPoint: Obesity - UK Drug Forecast and Market Analysis to 2022 Summary After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies ...

  • Industries : Pathology
  • Countries : United Kingdom
2014 Analysis of the UK Clinical Chemistry and Immunodiagnostic Market: Sales Forecasts, Supplier Shares, Competitive Strategies

2014 Analysis of the UK Clinical Chemistry and Immunodiagnostic Market: Sales Forecasts, Supplier Shares, Competitive Strategies

  • $ 3 950
  • Industry report
  • October 2013
  • by Venture Planning Group

2014 Analysis of the UK Clinical Chemistry and Immunodiagnostic Market: Sales Forecasts, Supplier Shares, Competitive Strategies is a new strategic analysis of major business opportunities emerging in ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
NeisVac-C (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

NeisVac-C (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • September 2013
  • by Global Data

NeisVac-C (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Summary Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset ...

  • Industries : Drug and Medication
  • Countries : United Kingdom, World
Physician Views: How do European cardiologists perceive oral anticoagulants versus warfarin? – Is Eliquis, Pradaxa or Xarelto their favoured option?

Physician Views: How do European cardiologists perceive oral anticoagulants versus warfarin? – Is Eliquis, Pradaxa or Xarelto their favoured option?

  • $ 645
  • Industry report
  • September 2013
  • by Firstword Pharma

Sales forecasts for Bristol-Myers Squibb and Pfizer's anticoagulant product Eliquis have declined notably in recent months. According to Bloomberg, current consensus estimates suggest 2018 global revenues ...

  • Industries : Drug and Medication
  • Countries : Europe, United Kingdom, United States
Physician Views – How do European cardiologists perceive oral anticoagulants versus warfarin? – Is Eliquis, Pradaxa or Xarelto their favoured option?

Physician Views – How do European cardiologists perceive oral anticoagulants versus warfarin? – Is Eliquis, Pradaxa or Xarelto their favoured option?

  • $ 645
  • Industry report
  • September 2013
  • by Firstword Pharma

Scope Sales forecasts for Bristol-Myers Squibb and Pfizer's anticoagulant product Eliquis have declined notably in recent months. According to Bloomberg, current consensus estimates suggest 2018 global ...

  • Industries : Drug and Medication
  • Countries : Europe, United Kingdom, United States
UK Injectables Market Outlook to 2017

UK Injectables Market Outlook to 2017

  • $ 1 200
  • Industry report
  • September 2013
  • by RNCOS

Injectables occupy a considerable prominence in UK irrespective of diminishing growth in the pharmaceutical market for 2-3 years. The advancements in technology up-gradation and investments have provided ...

  • Industries : Pharmaceutical, Drug and Medication, Pathology
  • Countries : United Kingdom
PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • July 2013
  • by Global Data

PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis ...

  • Industries : Drug and Medication, Pathology
  • Countries : United Kingdom
Albiglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Albiglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Company report
  • July 2013
  • by Global Data

Albiglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Albiglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type ...

  • Industries : Drug and Medication, Pathology
  • Countries : United Kingdom
PharmaPoint: Postmenopausal Vaginal Atrophy - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Postmenopausal Vaginal Atrophy - UK Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • July 2013
  • by Global Data

PharmaPoint: Postmenopausal Vaginal Atrophy - UK Drug Forecast and Market Analysis to 2022 Summary Although the postmenopausal vaginal atrophy (PVA) market has experienced anemic growth over the past decade, ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Company report
  • July 2013
  • by Global Data

Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Dulaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type ...

  • Industries : Pathology, Drug and Medication
  • Countries : United Kingdom
Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Company report
  • July 2013
  • by Global Data

Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type ...

  • Industries : Pathology, Drug and Medication
  • Countries : United Kingdom
Ear Care in the United Kingdom

Ear Care in the United Kingdom

  • $ 898
  • Industry report
  • July 2013
  • by Euromonitor International

Volume sales of ear care products fell by 1% in 2012, a significantly poorer performance than that seen over the review period. Consumers’ cautious spending continued, and some consumers were less willing ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
Emergency Contraception in the United Kingdom

Emergency Contraception in the United Kingdom

  • $ 898
  • Industry report
  • July 2013
  • by Euromonitor International

In 2012, emergency contraception increased by 3% in current value terms, to reach £25 million. After the introduction of OTC emergency contraceptive pills in 2001, growth was initially rapid, as women ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
OTC Triptans in the United Kingdom

OTC Triptans in the United Kingdom

  • $ 898
  • Industry report
  • July 2013
  • by Euromonitor International

In 2012 OTC triptans increased by 19% in current value terms to reach £7 million. Consumers continued to suffer from rising anxiety and stress levels, caused by concerns over their jobs and financial ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA

Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA

  • $ 645
  • Industry report
  • July 2013
  • by Firstword Pharma

Scope of the Report European-based endocrinologists are currently getting to grips with two new products that have been rejected for approval in the US market. Novo Nordisk’s long-acting basal insulin ...

  • Industries : Drug and Medication, Pathology
  • Countries : Europe, United Kingdom, United States
PharmaPoint: Chronic Heart Failure - United Kingdom Drug Forecast and Market Analysis to 2022

PharmaPoint: Chronic Heart Failure - United Kingdom Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • June 2013
  • by Global Data

PharmaPoint: Chronic Heart Failure - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Chronic Heart Failure - United Kingdom ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • June 2013
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
2013 Drugs of Abuse Testing in the UK: Hospitals and Commercial Labs

2013 Drugs of Abuse Testing in the UK: Hospitals and Commercial Labs

  • $ 2 450
  • Industry report
  • June 2013
  • by Venture Planning Group

This new 260-page report from Venture Planning Group provides a comprehensive analysis of the UK drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
2013 Drugs of Abuse Testing in Europe: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers

2013 Drugs of Abuse Testing in Europe: Hospitals, Commercial Labs, Physician Offices, Ambulatory Care Centers

  • $ 6 500
  • Industry report
  • June 2013
  • by Venture Planning Group

This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, ...

  • Industries : Drug and Medication
  • Countries : Germany, United Kingdom, Italy, Spain
2013 Endocrine Function Testing Market in the UK: Hospitals and Commercial Labs

2013 Endocrine Function Testing Market in the UK: Hospitals and Commercial Labs

  • $ 2 450
  • Industry report
  • June 2013
  • by Venture Planning Group

This new 269-page report from Venture Planning Group provides a comprehensive analysis in the UK endocrine function market, including emerging tests, technologies, instrumentation, sales forecasts by country, ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
2013 Therapeutic Drug Monitoring (TDM) Market in the UK: Hospitals and Commercial Labs

2013 Therapeutic Drug Monitoring (TDM) Market in the UK: Hospitals and Commercial Labs

  • $ 2 450
  • Industry report
  • June 2013
  • by Venture Planning Group

This new 247-page report from Venture Planning Group provides a comprehensive analysis of the UK therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022

PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • May 2013
  • by Global Data

PharmaPoint: Hepatitis C Virus - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus - United Kingdom Drug ...

  • Industries : Drug and Medication
  • Countries : United Kingdom
Bristol-Myers Squibb Co in Consumer Health (World)

Bristol-Myers Squibb Co in Consumer Health (World)

  • $ 532
  • Company report
  • February 2013
  • by Euromonitor International

Bristol-Myers Squibb Co, a US-based producer of pharmaceutical and consumer health products, is making increasingly definite steps away from consumer health in order to re-position itself as a bio-pharma ...

  • Industries : Healthcare
  • Countries : United States, United Kingdom, Europe, World
PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • February 2013
  • by Global Data

PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022”. ...

  • Industries : General Medicine and Specialty Medicine, Pathology, Drug and Medication
  • Countries : United Kingdom
PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022

PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022

  • $ 4 995
  • Industry report
  • January 2013
  • by Global Data

PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: HIV - United Kingdom Drug Forecast and Market Analysis ...

  • Industries : Drug and Medication, Pathology
  • Countries : United Kingdom
Quad 2 (HIV) - Forecast and Market Analysis to 2022

Quad 2 (HIV) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2013
  • by Global Data

Quad 2 (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Quad 2 (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency ...

  • Industries : Pathology, Drug and Medication
  • Countries : France, Germany, Italy, Spain, United Kingdom, Japan, Brazil, China
About 1 700 reports

Download Unlimited Documents from Trusted Public Sources

Smoking Treatment Industry in the UK

  • April 2015
    3 pages
  • Smoking Treatme...  

    Smoking Statist...  

    Cigarette  

  • United Kingdom  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.